HIGHLIGHTS
SUMMARY
Use of HTA to inform reimbursement decisions is increasing and represent a financial factor that is likely to influence innovation of antibiotics, yet little is known about HTA agencies response to the challenges linked to making new effective antibiotics available. While most of the literature pertaining to incentivizing antibiotic R and amp;D has focused on the role of new financial incentives and payment models, there is an increasing interest in regulatory authorities and HTA agencies role in stimulating innovation of antibiotics targeting unmet needs, including resistant bacteria. The authors identify barriers and facilitators . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.